How To Deal With High Dose Opioids: Better Storage, Disposal And Advertising
Executive Summary
Beyond considering removal from the market, US FDA advisory panel suggests actions agency could take to improve the safety of higher dosage strength opioids.
You may also be interested in...
Will US FDA Remove Higher Strength Opioids From The Market?
Advisory committee members are divided on whether agency should restrict access to higher dose opioids, but most want option kept on the table.
Opioid Blister Pack Mandate Could Be Phased-In Based On Prescription Volume
US FDA seeks public input on potential advantages and challenges of requiring 5-, 10, and -15-count blister packs for certain opioids and the idea of staggering implementation.
US FDA’s Confidentiality Policies Seen As Big EUA Shortcoming
System needs to be changed to enable US FDA to share COVID-19 application data and inspection reports with other regulatory authorities, stakeholders urge. Merck’s Julie Gerberding and former FDA Commissioner Hamburg criticize company announcement of data via press release prior to submission.